Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Hemorrhage 13 Neoplasms 7 Leiomyoma 6 Breast Neoplasms 6 Hematologic Neoplasms 4 Thrombocytopenia 3 Postoperative Hemorrhage 3 Meningioma 3 Urinary Bladder Neoplasms 2 Stomach Neoplasms 2 Seroma 2 Prostatic Neoplasms 2 Ovarian Neoplasms 2 Myofibroma 2 Head and Neck Neoplasms 2 Colonic Neoplasms 2 Brain Neoplasms 2 Bone Neoplasms 2 Blood Loss, Surgical 2 Wrist Fractures 1 Urologic Diseases 1 Urinary Retention 1 Thromboembolism 1 Skin Neoplasms 1 Seizures 1 Sarcoma 1 Recurrence 1 Postoperative Complications 1 Polyposis, Gastric 1 Pituitary Neoplasms 1

Interventions

Cyclophosphamide 151 Dexamethasone 140 Rituximab 83 fludarabine 78 Cytarabine 69 Lenalidomide 68 Bortezomib 63 fludarabine phosphate 62 Gemcitabine 62 venetoclax 54 Etoposide 53 pembrolizumab 52 pomalidomide 48 Paclitaxel 48 Cisplatin 47 Carboplatin 47 Peripheral Blood Stem Cell Transplantation 46 Filgrastim 40 Radiotherapy 39 Calcium Dobesilate 36 Busulfan 36 Methotrexate 34 Melphalan 34 Bevacizumab 33 carfilzomib 32 Cyclosporine 32 Azacitidine 32 Mycophenolic Acid 29 Vincristine 28 Temozolomide 28

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × Recurrence × Tranexamic Acid × Clear all

NCT05899465 2025-03-18

PRIME

University of Aarhus

Phase 3 Recruiting

Melanoma, Neoplasms, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon ⚡